PROS1 and Rare hereditary thrombophilia: The present study suggests that HA therapy should be recommended to increase the rate of live births in patients with thrombophilia who do not meet the diagnostic criteria for APS – non‐criteria APS, SNAPS, protein S deficiency, factor XII deficiency or increased platelet aggregation – if no live births occurred after two or more LDA treatments.